Lower chemo dose may prevent transplant complications

NCT ID NCT07319000

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a low dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (GVHD) — a common and serious complication where donor cells attack the patient's body. The trial involved 35 adults with various blood diseases who received a transplant from a related donor. The goal was to see if the low dose could keep severe GVHD rates low while helping blood cells recover faster.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

cyclophosphamide

What this could lead to

If it works, this could offer a safer way to prevent graft-versus-host disease after stem cell transplants, with faster blood cell recovery.

What could go wrong

This is a small, early-phase trial with only 35 participants. The low dose may not be as effective as standard doses, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia aplastic anemia chronic myelogenous leukemia, BCR-ABL1 positive chronic myelomonocytic leukemia Hodgkins lymphoma myelodysplastic syndrome non-Hodgkin lymphoma graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Universitario de Monterrey

    Monterrey, 64460, Mexico